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ABSTRACT 
Drug-induced photosensitivity refers to the development of cutaneous disease as a result of combined effects of a chemical and 
light. Photosensitivity reactions may result from systemic medications and topically applied compounds. Pirfenidone is known 
to cause photosensitivity reactions, rash, pruritus and dry skin at high doses. However, similar adverse reactions with low doses 
of Pirfenidone have not been reported. We report a case of photosensitivity reaction induced by low- dose Pirfenidone in a 
patient with idiopathic pulmonary fibrosis (IPF).  
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irfenidone is an orally administered, synthetic, 
pyridone compound that is approved in India in 
2010 for the treatment of adults with mild to 
moderate idiopathic pulmonary fibrosis (IPF).  The effects 
of pirfenidone are multitargeted as antioxidant, anti-
transforming growth factor (antiTGF) and anti-platelet 
derived growth factor effects have been demonstrated [1]. 
It also regulates the activity of TGF-ß and TNF-ɑ [1]. 
Pirfenidone inhibits cell proliferation, apparently by 
inhibiting DNA synthesis, in human myometrial and 
leiomyoma cells and also decreases the levels of mRNAs 
encoding collagen I and collagen III in these cells [2]. 
Also, pirfenidone also has been shown to inhibit 
pulmonary fibroblast expression of heat shock protein 47, 
a collagen-specific molecular chaperone that is thought to 
play an important role in extracellular matrix synthesis and 
remodeling. [3] 
 The safety profile of pirfenidone is excellent, and it 
appears to be generally well tolerated.  The most common 
adverse effects include gastrointestinal upset (64%), and 
fatigue (42%); therefore, drug is to be taken after food, to 
reduce the nausea and dizziness associated with the drug 
[4]. A plethora of dermatologic problems including 
photosensitivity reactions (24%) have also been reported, 
especially at high doses [4]. However, similar adverse 
reactions with low doses of Pirfenidone have not been 
reported. We report a case of rash, scaly plaques and hyper 
pigmentation of skin induced by low- dose pirfenidone in a 
female patient diagnosed with IPF.  
CASE REPORT 
The case involved a 54 year old female diagnosed with IPF 
in December 2012 and on treatment with pirfenidone 
200mg three times a day (600mg/day) orally since 
February 2013. The diagnosis of IPF was based on history, 
clinical symptoms and high resolution computed 
tomography (HRCT) scan findings. She was also on 
Montelukast 10mg, once daily orally since last 2 months 
(April 2015) for allergic bronchitis. The patient presented 
on 13th June 2015 (2 years 4 months after pirfenidone 
P 
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initiation), with features of rash, scaly papules and hyper 
pigmentation on right forearm accompanied with severe 
itching for 5 days. The last dose of pirfenidone was taken 
on 12th June 2015. The drug was immediately stopped and 
dermatology consultation was taken. A provisional 
diagnosis of drug induced photosensitivity reaction with 
pirfenidone was made on the basis of medical history and 
clinical examination. The differential diagnosis of actinic 
lichen planus was also considered.  
    
Figure 1 - Skin reaction at the time of presentation. Figure 2 - Skin reaction after one week of Pirfenidone discontinuation 
On laboratory investigations, her hemoglobin was low 
(9.8 g/dl), and absolute eosinophill count (AEC) was 
raised (440/mm3). Rest of the tests including leukocyte and 
platelet counts, hepatic and renal function tests were 
within normal limits. Biopsy of the skin lesions was 
planned but the patient refused the biopsy examination. As 
the patient was on low dose Pirfenidone therapy (600 
mg/day), she was completely weaned off the drug and was 
treated with oral predisolone and antihistamines. She was 
advised to avoid direct exposure to sunlight, including sun 
lamps, and to use protective clothing. A sun-screening 
agent was prescribed. The skin reaction showed significant 
recovery at the end of one week of pirfenidone 
discontinuation. This observation enforced the initial 
diagnosis of pirfenidone induced photosensitivity reaction. 
Re-challenge after recovery from the reaction was not 
performed. 
DISCUSSION 
Skin-related adverse events in the context of pirfenidone 
therapy can manifest as an erythematous or as a phototoxic 
burn-like skin rash, occurring on sun-exposed body areas 
[5]. The underlying mechanism of pirfenidone in 
photosensitivity reactions is likely to be phototoxic and 
related to the drug’s ability to absorb both ultraviolet (UV) 
B and UVA [4]. Absorption of UV light by pirfenidone in 
skin tissue leads to generation of reactive oxygen species 
and lipid peroxidation resulting in skin lesions [6]. 
Preclinical animal studies have hypothesized that 
pirfenidone-induced skin reactions are phototoxic, and 
therefore proportional to light exposure and drug 
concentration [7]. Also, it has been demonstrated that the 
use of a sunscreen with a high protection factor 
significantly reduces the severity of skin reactions [7]. 
In the CAPACITY clinical studies with pirfenidone, 
the most commonly observed skin-related adverse events 
were photosensitivity reactions and rash. Photosensitivity 
reaction led to discontinuation in 0.9% pirfenidone-treated 
patients [8]. In one study which evaluated both high (1800 
mg/day) and low-dose (1200 mg/day) pirfenidone 
compared to placebo, photosensitivity was significantly 
more common in the pirfenidone-treated subjects 
regardless of dose [9]. A similar photosensitivity reaction 
with high dose pirfenidone therapy (600mg/d for 5 months 
followed by escalation to 1200 mg/d for 10 days) was 
reported in an elderly man with IPF [10].  
 Analysis of another clinical trial population showed 
that skin-related adverse events had a tendency to occur 
early in the course of treatment and decrease over time 
[11]. Kaplan-Meier estimates of time to photosensitivity 
reaction were analyzed in one study. In pirfenidone 
treatment groups, most patients experiencing 
photosensitivity or rash did so within the first 24 weeks of 
treatment.  Also in this group, the frequency of 
photosensitivity reaction or rash was shown to be 
increased in March, peaked in June, and declined in the 
autumn. This pattern was not observed in patients treated 
with placebo. Thus, it was proposed that there may be a 
significant association of these events to sun exposure in 
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patients treated with pirfenidone [12].  In our patient, the 
reaction occurred in the month of June, the dose used was 
low (600 mg/day), and the duration of treatment was 
longer (2 years). Hence, pirfenidone induced 
photosensitivity may not be only dose related and further 
research should also focus on the duration of therapy.  
 The standard approach for preventing and managing 
skin adverse events includes avoiding exposure to direct 
sunlight (including sunlamps), use of sunscreen active 
against both UVA and UVB, use of protective clothing, 
and avoidance of other medicinal products known to cause 
photosensitivity [12]. Patients experiencing a severe 
photosensitivity event of sun-exposed skin should be 
instructed for temporary discontinuation of Pirfenidone, 
until the skin reaction normalizes. The potential limitation 
of this case report was that the patient was not re-
challenged with pirfenidone after the photosensitivity 
reaction had subsided.  
CONCLUSION 
Pirfenidone therapy is generally well tolerated; although, it 
may require discontinuation of therapy due to skin-related 
adverse events. In this case, the patient developed 
photosensitivity reaction with low dose pirfenidone 
therapy (600 mg/day). Clinicians should monitor the dose 
and duration of treatment with pirfenidone to prevent 
occurrence of such reactions.  
Acknowledgements 
Dr Rajendra Prasad, Junior Resident, Department of 
Respiratory Medicine, Nizam’s Institute of Medical 
Sciences (NIMS), Hyderabad. 
REFERENCES 
1. Hilberg O, Simonsen U, du Bois R, Bendstrup E. 
Pirfenidone: significant treatment effects in idiopathic 
pulmonary fibrosis. Clin Respir J. 2012; 6: 131–143. 
2. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel 
pharmacological agent that inhibits leiomyoma cell 
proliferation and collagen production. J Clin Endocrinol 
Metab. 1998; 83: 219-23. 
3. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, 
Yoshioka S, Soda H, et al. Pirfenidone inhibits the 
expression of HSP47 in TGF-beta1-stimulated human 
lung fibroblasts. Life Sci. 2008; 82: 210–217. 
4. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment 
of idiopathic pulmonary fibrosis with a new antifibrotic 
agent, pirfenidone: results of a prospective, open-label 
Phase II study. Am J Respir Crit Care Med. 1999; 159: 
1061–1069. 
5. Costabel U, Bendstrup E, Cottin V, Dewint P, Egan 
JJ, Ferguson J, et al. Pirfenidone in Idiopathic Pulmonary 
Fibrosis: Expert Panel Discussion on the Management of 
Drug-Related Adverse Events. Adv Ther. 2014; 31: 375–
391. 
6. Seto Y, Inoue R, Kato M, Yamada S, Onoue S.  
Photosafety assessments on pirfenidone: photochemical, 
photobiological, and pharmacokinetic characterization. J 
Photochem Photobiol B. 2013; 120: 44-51. 
7. Pharmaceuticals and Medical Devices Agency Japan. 
Pirfenidone report. Available at 
http://www.pmda.go.jp/english/service/pdf/drugs/pirespa_
oct2008_e.pdf. [Last accessed on Feb 10, 2016]. 
8. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg 
MK, Kardatzke D et al. CAPACITY Study Group. 
Pirfenidone in patients with idiopathic pulmonary fibrosis 
(CAPACITY): two randomized trials. Lancet. 2011; 377: 
1760-9. 
9. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, 
Suga M, et al. Pirfenidone in idiopathic pulmonary 
fibrosis. Eur Respir J. 2010; 35: 821-9. 
10. Gaikwad RP, Mukherjee SS. Pirfenidone induced 
phototoxic reaction in an elderly man.  IJDVL 2016; 82; 
101-103. 
11. Valeyre D, Albera C, Bradford WZ.  Comprehensive 
assessment of the long-term safety of pirfenidone in 
patients with idiopathic pulmonary 
fibrosis. Respirology. 2014: 19: 740–748. 
12. PIRFENIDONE Capsules - Food and Drug 
Administration. Available at 
www.fda.gov/downloads/AdvisoryCommittees/.../UCM2
03083.pdf. [Last accessed on Feb 06, 2016]. 
13. European Medicine Agency. Esbriet
®
 (pirfenidone) 
Summary of product characteristics. Available at 
http://www.ema.europa.eu/docs/en_GB/document_library
/EPAR_Product_Information/human/002154/WC5001030
49.pdf. [Last accessed on Feb 05, 2016].  
 
 
 
 
 
How to cite this article: Usharani P, Ramakanth GSH, 
Paramjyothi GK, Vijayalakshmi S, Reddy DB. Pirfenidone 
Induced Photosensitivity Reaction in a Patient with 
Idiopathic Pulmonary Fibrosis. Indian J Case Reports. 
2016; 2 (1): 11-13. 
Conflict of interest: None stated, Funding: Nil 
